Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance
Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.97, $0.38 better than the analyst estimate of $3.59. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.68 billion.
GUIDANCE:
Amgen sees FY2019 EPS of $13.75-$14.30, versus the consensus of $13.97. Amgen sees FY2019 revenue of $22.4-22.9 billion, versus the consensus of $22.59 billion.
For earnings history and earnings-related data on Amgen (AMGN) click here.
